SBFM Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
9.3M
+14.5%
8.1M
-5.7%
8.6M
-8.9%
9.4M
+0.1%
9.4M
Cost of Revenue
6.8M
+15.7%
5.9M
+6.5%
5.5M
-12.5%
6.3M
+6.0%
6.0M
Gross Profit
2.4M
+11.3%
2.2M
-28.0%
3.0M
-1.5%
3.1M
-10.2%
3.4M
Operating Expenses
4.0M
+12.9%
3.6M
-25.8%
4.8M
+15.8%
4.2M
-24.1%
5.5M
R&D
13.2K
-58.3%
31.7K
-56.8%
73.5K
-38.4%
119.3K
-39.2%
196.2K
SG&A
3.2M
+1.7%
3.1M
-21.9%
4.0M
+36.3%
2.9M
-9.7%
3.2M
Operating Income
-1612858
-15.6%
-1395597
+22.0%
-1790011
-64.7%
-1086613
+47.1%
-2054655
EBITDA
-1203881
+2.1%
-1229662
+15.8%
-1459703
-501.2%
-242791
+71.6%
-855408
Net Income
-1564048
-25.7%
-1243869
+41.9%
-2140927
-142.2%
-883820
+50.1%
-1770834
EPS (Basic)
$-1.15
+54.0%
$-2.50
-4.2%
$-2.40
-26.3%
$-1.90
+51.8%
$-3.94
EPS (Diluted)
$-1.15
+54.0%
$-2.50
-4.2%
$-2.40
-26.3%
$-1.90
+51.8%
$-3.94
Shares (Diluted)
1.4M
+178.3%
490.6K
-45.0%
891.9K
+95.8%
455.6K
+1.3%
449.6K
Sunshine Biopharma (SBFM) โ€” Financials